[PRESS RELEASE] – SAVONA, Italy, June 24, 2025 – Tilray Medical, a division of Tilray Brands Inc. and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and health care practitioners to make informed individualized health decisions, announced a significant milestone in its European expansion with the introduction of three new medical cannabis flower varieties in Italy.
Through its wholly-owned subsidiary, FL Group, Tilray has become the first company in Italy to receive official authorization from the Ministero della Salute (Italian Ministry of Health) to import and distribute proprietary Tilray Medical-branded medical cannabis flower for therapeutic use.
Beginning this month, the following Tilray Medical products are approved for therapeutic use in Italy and available for distribution through pharmacies across Italy:
- Tilray THC 25%
- Tilray THC 18%
- Tilray THC 9% / CBD 9%
“This milestone underscores the vital role of medical cannabis as a therapeutic medicine for patients in need, supporting their health and well-being,” Denise Faltischek, chief strategy officer and head of International at Tilray Brands, said.
“We are proud to expand our medical cannabis portfolio in Italy with the introduction of our Tilray Medical high-quality, EU-GMP certified medical cannabis products that uphold the highest standards in patient care,” Faltischek said. “We extend our gratitude to the Ministero della Salute for their trust in Tilray Medical and for providing the necessary regulatory framework to ensure access to safe, consistent and reliable cannabinoid-based therapies. Together, we are advancing health care and patient wellness through innovation and collaboration.”
Tilray continues to lead the European medical cannabis market with operations in Germany, Italy, Portugal, Poland and the United Kingdom, offering a broad portfolio of EU-GMP certified medical cannabis products.
